908112-37-8

908112-37-8 structure

Name: AT-533
Chemical Name: AT-533
CAS Number: 908112-37-8
Molecular Formula: C₂₃H₃₀N₄O₃
Molecular Weight: 410.51
Catalog: Signaling Pathways Anti-infection HSV
Create Date: 2023-04-04 14:33:09
Modify Date: 2025-08-25 16:44:56
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs)[1][2][3].

Name	AT-533

Description	AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs)[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Anti-infection >> HSV Signaling Pathways >> Metabolic Enzyme/Protease >> HSP Research Areas >> Infection Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FAK Signaling Pathways >> PI3K/Akt/mTOR >> Akt Research Areas >> Inflammation/Immunology Signaling Pathways >> Cell Cycle/DNA Damage >> HSP Signaling Pathways >> Metabolic Enzyme/Protease >> HIF/HIF Prolyl-Hydroxylase Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR Signaling Pathways >> MAPK/ERK Pathway >> ERK Signaling Pathways >> Stem Cell/Wnt >> ERK
Target	HSP90 HSV-1 ERK1 ERK2 NF-κB Akt HIF-1α VEGF/VEGFR-2
In Vitro	AT-533 (0-1350 nM; 24 h 或 48 h) 抑制 20ng/mL VEGF 诱导的管形成、细胞迁移和 HUVEC侵袭[1]。 AT-533 (2 μM 或 75 μM; 24 h) 抑制缺氧诱导的乳腺癌细胞中 HIF-1α/VEGF 信号通路，抑制 Akt/mTOR/p70S6K, Erk1/2 和 FAK 磷酸化[1]。 AT-533 (10 nM, 50 nM; 48 h) 对绒毛膜 (CAM) 模型具有抗血管生成能力[1]。 AT-533 (0.5 μM; 2 h, 4 h) 降低 RAW264.7 和 BV2 细胞受 HSV-1 诱导引起 TNF-α、IL-1β 和 IL-6 的产生[2]。 Cell Viability Assay[1] Cell Line: Human umbilical vein endothelial cells (HUVECs): MCF-7 and MDA-MB-231 Concentration: 0, 5.6, 16.7, 50, 150, 450, and 1350 nM Incubation Time: 12 h, 24 h, 48 h, and 72 h Result: Inhibited cell viability at 48 h with an IC50 value of 50.1 nM. Western Blot Analysis[1] Cell Line: MCF-7 cells and MDA-MB-231 cells Concentration: 5 nM, 10 nM, 50 nM, and 75 nM Incubation Time: 24 h Result: Inhibited the phosphorylation of VEGF-2, Akt, mTOR, Erk1/2, FAK.
In Vivo	AT-533 (10 mg/kg; 腹腔注射; 每天 1 次，共 21 天) 抑制小鼠 MDA-MB-231 乳腺癌异种移植瘤模型中 HIF-1α/VEGF 信号通路相关蛋白的表达[1]。 AT-533 (1, 2, 4 mg/kg; 腹腔注射; 每天 1 次，共 30 天) 在 Sprague-Dawley 大鼠的亚急性毒性试验中，不引起死亡、食欲下降、体重下降、不良反应[3]。 Animal Model: Male C57BL/6 mice with MDA-MB-231 breast cancer xenografts[1] Dosage: 10 mg/kg; Administration: Intraperitoneal injection; once daily for 21 days Result: Significantly downregulated HIF-1α and VEGF expression.
References	[1]. Zhang PC, et al. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo. Biochem Pharmacol. 2020 Feb;172:113771. [2]. Li F, et al. AT-533, a Hsp90 inhibitor, attenuates HSV-1-induced inflammation. Biochem Pharmacol. 2019 Aug;166:82-92. [3]. Wu Y, et al. Subacute toxicological evaluation of AT-533 and AT-533 gel in Sprague-Dawley rats. Exp Ther Med. 2021 Jun;21(6):632.

Molecular Formula	C₂₃H₃₀N₄O₃
Molecular Weight	410.51

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

908112-37-8	162640-98-4
16810-17-6	31570-04-4
2170729-29-8	74550-97-3
80155-82-4	4813-11-0
835872-35-0	211364-06-6
1782316-44-2	179260-14-1
1260840-67-2	33684-15-0
1369155-13-4	1551320-42-3
1864060-44-5	1780123-36-5
2922227-31-2	1783342-53-9